Huons Global announced Wednesday a strategic distribution and co-promotion agreement with Sanofi Korea, officially entering the vaccine market.
The agreement, effective April 1st, grants Huons responsibility for the domestic distribution and co-promotion of five key vaccines: the influenza vaccines Vaxigrip and Efluelda, the Tdap vaccine Adacel, the Hepatitis A vaccine Avaxim, and the meningococcal vaccine MenQuadfi.
This partnership leverages Sanofi’s robust vaccine portfolio alongside Huons’ established strengths in injectable drug sales and its reliable cold-chain logistics, creating anticipated synergies within the South Korean vaccine market.
To support this new venture, Huons has established a dedicated vaccine business unit. The company plans to utilize its extensive sales network to improve vaccine accessibility across the nation.
Furthermore, Huons will leverage its pre-existing cold-chain infrastructure – developed through the distribution of temperature-sensitive injectable drugs – to ensure the stable and secure delivery of vaccines to healthcare providers.
“This partnership with Sanofi marks a pivotal moment in Huons’ evolution as a global public health partner,” stated Huons Global CEO Song Soo-young. “By combining Sanofi’s innovative vaccine products with our local market expertise, we aim to establish a new benchmark within the Korean market.”
Huons intends to further expand its vaccine portfolio through additional partnerships with leading global biopharmaceutical companies, positioning vaccines as a crucial driver for future growth.
jwjeon7625
